Autism/ID Panel
New York
Approved
Genes
Conditions
- Intellectual disability
- Kabuki syndrome (KS)
- Rubinstein-Taybi syndrome (RSTS)
- Autism spectrum disorders
Clinical Utility
- Molecular confirmation of a clinical diagnosis
- To assist with decisions about treatment and management of individuals with autism or intellectual disability
- Testing of at-risk relatives for specific known variant(s) previously identified in an affected family member
Lab Method
- Next-Gen Sequencing
- Deletion/Duplication Analysis
The American College of Medical Genetics and Genomics (ACMG) strongly supports exome or genome sequencing as a first-tier test for patients with developmental delay, intellectual disabilities and/or congenital anomalies.
References:
- Genetics in Medicine (2021) 23:2029–2037; https://doi.org/10.1038/s41436-021-01242-6
Test Code
T395
CPT Codes*
81404x2, 81405x3, 81406x4, 81407x1, 81408x1, 81175x1, 81185x1, 81302x1, 81304x1, 81321x1, 81323x1, 81479x3
ABN Required
No
Turnaround Time**
4 weeks
Preferred Specimen
Alternative Specimen
*The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.
**Turnaround times are estimates and begin once the sample(s) begin processing at the GeneDx lab and could be extended in situations outside GeneDx’s control.
Test Documents
Billing
For Providers
Targeted Variant Testing